Green tea mist tested against COVID lung inflammation in cancer patients

NCT ID NCT06924749

Completed Disease control Sponsor: Shandong Cancer Hospital and Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 2 trial tested whether inhaling a green tea extract called EGCG could help cancer patients with moderate-to-severe COVID-19 pneumonia. 111 participants received either EGCG mist or a placebo three times daily for 7 days. The study looked at lung CT scan improvements, symptom relief, and safety. EGCG is known for anti-inflammatory and antiviral effects, but results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EGCG (epigallocatechin-3-gallate), a green tea extract, given as an inhaled mist
What this could lead to: If it works, this could offer a safe, plant-based treatment option for COVID-19 pneumonia in cancer patients, reducing lung inflammation and improving recovery.
What could go wrong: This is a small, completed Phase 2 trial with no published results yet. The benefit may be modest or not better than standard care, and the findings may not apply to non-cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER PATIENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer COVID-19 interstitial lung disease non-specific interstitial pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER PATIENTS PNEUMONIA, INTERSTITIAL

Contacts and locations

Locations

Hanxi Zhao

Jinan, Shandong, Shandong Cancer Hospital, China
Shan Dong cancer hospital and institute

Jinan, Shandong, 250117, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.